Champions Oncology
CSBR
32 hedge funds and large institutions have $46.8M invested in Champions Oncology in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 3 closing their positions.
1,079% more call options, than puts
Call options by funds: $1.88M | Put options by funds: $159K
0.12% more ownership
Funds ownership: 46.01% → 46.14% (+0.12%)
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
6% less capital invested
Capital invested by funds: $49.8M → $46.8M (-$3.02M)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
+$460K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$173K |
| 3 |
E
Ergoteles
New York
|
+$117K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$70.8K |
| 5 |
Morgan Stanley
New York
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$386K |
| 2 |
Renaissance Technologies
New York
|
-$179K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$85.5K |
| 4 |
OMC
Overbrook Management Corp
New York
|
-$83.6K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$61.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Morgan Stanley
New York
| $59K | +$20.1K | +2,400 | +44% |
|
27
Barclays
London,
United Kingdom
| $10K | +$11.2K | +1,342 | New |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$652 | +78 | +78% |
|
|
CAM
29
ClariVest Asset Management
San Diego,
California
| – | -$386K | -48,200 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$16K | -2,000 | Closed |
|
|
TCWM
31
Total Clarity Wealth Management
St. Charles,
Illinois
| – | -$7K | -937 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$125 | -15 | -45% |
|
33
Wells Fargo
San Francisco,
California
| – | -$25 | -3 | -7% |
|
CSBR Hedge Fund Activity: Q3 2022 in Review
32 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q3 2022, worth a combined $46.8M — down 6.1% from $49.8M a quarter earlier.
Fund positioning in CSBR was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 9 trimmed.
The largest buyer was Tocqueville Asset Management, adding an estimated $460K. The largest seller was ClariVest Asset Management, exiting entirely with an estimated $386K sold.
- 32 institutional investors held Champions Oncology (CSBR) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $46.8M of Champions Oncology stock for Q3 2022, down 6.1% quarter-over-quarter.
- 3 funds opened new Champions Oncology positions in Q3 2022 and 3 closed out, a net change of 0 holders.
- The largest Champions Oncology buyer in Q3 2022 was Tocqueville Asset Management, an estimated $460K added.
- The largest Champions Oncology seller in Q3 2022 was ClariVest Asset Management, an estimated $386K sold.
Based on aggregated 13F filings for Q3 2022.